Thursday, December 9, 2010

Use of Procalcitonin in Newborn to determine length of antibiotic therapy

BMC Pediatrics 2010

Martin Stocker , Wim JJ Hop and Annemarie MC van Rossum

BMC Pediatrics 2010, 10:89

Published:8 December 2010

Abstract (provisional)

Background

Early diagnosis and treatment of the newborn infant with suspected sepsis are essential to prevent severe and life threatening complications. Diagnosis of neonatal sepsis is difficult because of the variable and nonspecific clinical presentation. Therefore, many newborns with nonspecific symptoms are started on antibiotic treatment before the presence of sepsis has been proven. With our recently published single-centre intervention study we were able to show that Procalcitonin determinations allowed to shorten the duration of antibiotic therapy in newborns with suspected early-onset sepsis.

Methods

The study is designed as randomized controlled international multicenter intervention trial on the efficacy and safety of Procalcitonin guided treatment. Term and near-term infants (gestational age greater than or equal to 34 0/7 weeks) with suspected sepsis in the first 3 days of life requiring empiric antibiotic therapy will be included. The duration of antibiotic therapy in the standard group is based on the attending physician's assessment of the likelihood of infection (infection unlikely, possible, probable or proven). In the Procalcitonin group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive Procalcitonin values are within the normal range. Co-primary outcome measures are the duration of antibiotic therapy (superiority aspect of the trial) and the proportion of infants with a recurrence of infection requiring additional courses of antibiotic therapy and/or death in the first month of life (safety of study intervention, non-inferiority aspect of the trial). The number of infants to be included equals 800 per arm. With these numbers the power of the study to demonstrate superiority for duration of antibiotic therapy as well as non-inferiority regarding safety, i.e. excluding a disadvantage difference larger than 2% for the experimental arm, will both be greater than 80%.

Discussion

Benefit of the study is a possible limitation of unnecessary use of antibiotics. The results of our first study suggest that there is a low risk on discontinuing antibiotic treatment too early, resulting in the development of a neonatal infection with its morbidity and mortality. Trial registration: This trial is registered in the U.S. National Institutes of Health's register, located at http://www.clinicaltrials.gov. (NCT00854932).


From Introduction:

Another biomarker that has been discovered more recently, PCT, is proven to be a good marker of severe, invasive bacterial infections in children. All studies on severe, invasive bacterial infections in children report higher sensitivities and specificities of PCT than for CRP [12-16]. PCT is a 116–aminoacid peptide and one of the precursors of calcitonin. The physiological function of calcitonin remains unknown. No disorders attributable to either an excess or a deficiency of calcitonin have been identified. Most microbial infections induce a ubiquitous increase in CALC1 gene expression and a subsequent release of calcitonin precursors from all tissues and cell types throughout the body [17]. In bacterial infections, PCT increases from concentrations in the picogram range (below the detection level of current PCT assays) to plasma concentrations ranging from 1 to 1000 ng/ml. This increase often correlates with the severity of the disease and with mortality [18-21]. Increases in PCT occur more rapidly than increases in CRP. PCT can be detected in the plasma 2 hours after the injection of endotoxins. Within 6–8 hours, PCT concentrations rise and a plateau is reached after approximately 12 hours [22]. CRP can be detected in the plasma after 12 h and reaches a plateau after 20–72 hours. PCT and CRP decrease to their normal values after 2–3 days and 3–7 days, respectively [23-25].

The use of PCT as a marker of neonatal bacterial infection is complicated by several factors. First, infants with respiratory distress syndrome, hemodynamic failure, perinatal asphyxia, intracranial hemorrhage, pneumothorax, or after resuscitation have raised serum PCT concentrations that do not differ from those of septic neonates up to 48 h after onset of clinical signs of distress or infection [26-28]. Second, a physiological increase of PCT has been reported up to 48 h post partum [29]. Third, prepartum and intrapartum administration of antibiotics may affect PCT concentrations in the umbilical cord [30], and postnatal administration of antibiotics will decrease PCT concentrations more rapidly than CRP concentrations [31,32]. When these pitfalls are taken into account, PCT performs better than CRP in diagnosing neonatal bacterial infection.

Chiesa et al developed a nomogram for PCT [33] and Assumma and colleagues performed a longitudinal study on PCT values in healthy neonates [34]. In his findings Chiesa was able to report two major differences in between healthy and septic neonates which formed the basis of his nomogram. Firstly, the level of elevation in PCT was much higher in septic neonates versus healthy newborns and secondly, the absence of a decrease of PCT values after the initial cytokine release post-partum is indicative of a bacterial infection. With all PCT values being increased during the first two days of life, a reference range covering this time period with intervals of several hours is a tool to identify septic neonates. The adult reference ranges apply from three days after birth. Using PCT in this manner has been proven extensively to be a very reliable marker for the diagnosis of neonatal sepsis [35-39].

In recent years a novel indication for the use of PCT has been discovered, related to its described high negative value. It has been reported in many interventional trials [40-44] that a low PCT indicates the absence of a need for antimicrobial therapy. In several countries the recent adult intensive care guidelines have been altered to the extent that PCT has displaced CRP in the recommendations [45,46]. Applying this principle to neonatology, we performed a single-centre intervention trial in Lucerne, Switzerland that showed that serial PCT determinations allowed to shorten the duration of antibiotic therapy in term and near-term infants with suspected early-onset sepsis [47]. This study is designed to test the reliability of a PCT-based strategy in a larger cohort of neonates.

And, read on from the link.

Direct link to journal article on www.

Tuesday, December 7, 2010

22q11 microdeletion

requency of 22q11.2 microdeletion in children with congenital heart defects in Western Poland

Anna Wozniak email, Danuta Wolnik-Brzozowska email, Marzena Wisniewska email, Renata Glazar email, Anna Materna-Kiryluk email, Tomasz Moszura email, Magdalena Badura-Stronka email, Joanna Skolozdrzy email, Maciej Krawczynski email, Joanna Zeyland email, Waldemar Bobkowski email, Ryszard Slomski email, Anna Latos-Bielenska email and Aldona Siwinska email

BMC Pediatrics 2010, 10:88doi:10.1186/1471-2431-10-88

Published:6 December 2010

Abstract (provisional)

Background

The 22q11.2 microdeletion syndrome (22q11.2 deletion syndrome -22q11.2DS) refers to congenital abnormalities, including primarily heart defects and facial dysmorphy, thymic hypoplasia, cleft palate and hypocalcaemia. Microdeletion within chromosomal region 22q11.2 constitutes the molecular basis of this syndrome. The 22q11.2 microdeletion syndrome occurs in 1/4000 births. The aim of this study was to determine the frequency of 22q11.2 microdeletion in 87 children suffering from a congenital heart defect (conotruncal or non-conotruncal) coexisting with at least one additional 22q11.2DS feature and to carry out 22q11.2 microdeletion testing of the deleted children's parents. We also attempted to identify the most frequent heart defects in both groups and phenotypic traits of patients with microdeletion to determine selection criteria for at risk patients.

Methods

The analysis of microdeletions was conducted using fluorescence in situ hybridization (FISH) on metaphase chromosomes and interphase nuclei isolated from venous peripheral blood cultures. A molecular probe (Tuple) specific to the HIRA (TUPLE1, DGCR1) region at 22q11 was used for the hybridisation.

Results

Microdeletions of 22q11.2 region were detected in 13 children with a congenital heart defect (14.94% of the examined group). Microdeletion of 22q11.2 occurred in 20% and 11.54% of the conotruncal and non-conotruncal groups respectively. Tetralogy of Fallot was the most frequent heart defect in the first group of children with 22q11.2 microdeletion, while ventricular septal defect and atrial septal defect/ventricular septal defect were most frequent in the second group. The microdeletion was also detected in one of the parents of the deleted child (6.25%) without congenital heart defect, but with slight dysmorphism. In the remaining children, 22q11.2 microdeletion originated de novo.

Conclusions

Patients with 22q11.2DS exhibit wide spectrum of phenotypic characteristics, ranging from discreet to quite strong. The deletion was inherited by one child. Our study suggests that screening for 22q11.2 microdeletion should be performed in children with conotruncal and non-conotruncal heart defects and with at least one typical feature of 22q11.2DS as well as in the deleted children's parents.

Saturday, December 4, 2010

Rivaroxabon - Oral factor Xa inhibitor

NEJM dt. 12/04/10:
The EINSTEIN Investigators
Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.

METHODS

We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study.

RESULTS

The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin–vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). p="0.11).

CONCLUSIONS

Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193and NCT00439725.)

Thursday, November 11, 2010

Closure of ASD in adults

Benefit of Atrial Septal Defect Closure in Adults: Impact of Age
Humenberger M, Rosenhek R, Gabriel, et al.
Eur Heart J 2010;Oct 12:[Epub ahead of print].

Comments (3)Study Question:
What is the effect of age on the clinical benefit of atrial septal defect (ASD) closure in adults?
Methods:
A cohort of 236 patients undergoing transcatheter ASD closure at a single center was studied. Patients were divided into three groups based on age.
Group A included patients younger than age 40 (n = 78),
Group B included patients ages 40-60 (n = 84), and
Group C included patients older than 60 years (n = 74).
Pulmonary pressures, right ventricular size, and symptoms were assessed before and after device closure.

Results:
The mean age for the entire cohort was 49 ± 18 years. There was no difference in defect size (median 22 mm; interquartile range, 19-26 mm) or shunt ratio (Qp:Qs 2.2; interquartile range, 1.7-2.9). Pulmonary pressure and right ventricular size were significantly related to age. Right ventricular size (by two-dimensional echocardiogram measures) decreased in all groups. Post-procedure, the systolic pulmonary artery pressure (PAP) decreased from 31 ± 7 to 26 ± 5 mm Hg in group A, 37 ± 10 to 30 ± 6 mm Hg in group B, and 53 ± 17 to 43 ± 14 mm Hg in group C (p < 0.0001). Absolute changes in right ventricular size and PAP did not differ between the groups. Symptoms were present in 13%, 49%, and 83% of patients prior to the procedure, and 3%, 11%, and 34% of patients after the procedure in groups A, B, and C, respectively. Functional status was related to PAP.
Conclusions:
At any age, ASD closure is followed by symptomatic improvement, and decrease in right ventricular size and PAP.

Perspective:
Closure of ASD in adults of advancing age has long been an area of controversy in congenital cardiology. Most studies comparing defect closure with conservative management were done in the era of surgical closure and did not convincingly demonstrate a survival benefit. Most studies, including this one, demonstrate significant improvement in symptoms after closure of ASD. The impact on atrial arrhythmias is less clear. The minimal mortality and overall low complication rate of device closure make it an attractive option for older adults who may have multiple comorbidities. This study supports closure of ASDs in older adults, particularly for symptomatic relief. As patients with long-standing ASD may not appreciate their level of symptomatology, all patients with significant ASD should be strongly considered for device closure.
Author(s):
Timothy B. Cotts, M.D., F.A.C.C.

Modification to Extra-cardiac lateral tunnel Fontan - In situ pedicled pericardial tunnel.

JTCVS Volume 140, Issue 5, Pages 1076-1083 (November 2010)

In situ pericardial extracardiac lateral tunnel Fontan operation: Fifteen-year experience
Read at the 90th Annual Meeting of The American Association for Thoracic Surgery, Toronto, Ontario, Canada, May 1–5, 2010.

Nahidh W. Hasaniya, MD, PhDa, Anees J. Razzouk, MDa, Neda F. Mulla, MDb, Ranae L. Larsen, MDb, Leonard L. Bailey, MDa

Background
The study purpose is to evaluate the long-term outcome of the in situ pericardial extracardiac lateral tunnel Fontan operation.

Methods
From June 1994 to August 2009, 160 patients with single ventricle (boys, n = 96, 60%, median age = 39 months, mean weight 15.5 kg) underwent the pedicled pericardial extracardiac lateral tunnel operation. Patients' charts were reviewed for perioperative and long-term follow-up data, outcome, and mortality. The potential growth of these tunnels was evaluated.

Results
The main diagnoses included tricuspid atresia (n = 44, 27%); double-outlet right ventricle (n = 29, 18%), and hypoplastic left heart syndrome (n = 26, 16%). The mean follow-up was 6.5 ± 3.7 years (range: 0.1–15 years). There were 2 (1.3%) operative and 6 (3.7%) late deaths. Actuarial survival at 14 years was 93%. Early complications included prolonged effusions (n = 35, 22%), chylothorax (n = 5, 3.1%), readmissions (n = 35, 22%), cerebrovascular accidents (n = 8, 5%), contralateral phrenic nerve palsy (n = 1, 0.8%), and transient arrhythmias (n = 5, 3.1%). No pacemaker was needed. Late complications included tunnel stenosis (n = 3, 1.8%) managed with balloon dilatation and stenting in 2 patients and surgical revision in 1; tunnel thrombosis (n = 2, 1.2%) causing death in both patients; and protein losing-enteropathy (n = 4, 2.5%). Follow-up echocardiography of 10 patients showed laminar flow, no turbulence/gradient at the inferior vena cava and mid-tunnel levels. The diameter indexed to body surface area showed growth, reduction, or no change depending on flow demands.

Conclusions
The construction of the extracardiac lateral tunnel Fontan conduit using viable pedicled pericardium is a relatively simple, durable, and safe operation. Long-term follow-up confirms low morbidity and mortality. Fenestration is unnecessary in most patients. This viable tunnel adapts to physiologic flow demands.

Wednesday, November 10, 2010

How much is too much?!

A Heart With 67 Stents
Rami N. Khouzam, MD, Rajvir Dahiya, MD and Richard Schwartz, MD
Winthrop University Hospital, Mineola, New York

JACC 2010;56:1605

A 56-year-old male with coronary artery disease presented with angina, nonspecific electrocardiographic changes, and elevated troponins. Coronary angiography revealed total occlusion of a stent in the circumflex artery, where another was deployed—his 67th stent. The patient had 28 catheterizations over 10 years, with stents placed in his native coronary arteries as well as in 3 bypass grafts. All stents were placed to relieve his angina, refractory to maximal medical treatment and transmyocardial laser revascularization. Stents can be a great tool to help revascularization and relieve symptoms; unfortunately, they are prone to thrombosis and restenosis. If they fail while medical management is maximized unsuccessfully, alternative tools are lacking. This case raises many questions: "How much is too much?" "Are there guidelines?" and "What else can be offered for symptom relief?" More studies are needed to evaluate impact on quality of life versus risks in this multistent population. LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; OM = obtuse marginal branch of the circumflex coronary artery; RCA = right coronary artery.

CoreValve - Malposition and Correction

Publish ahead of print: Accessed Nov 10, 2010.
http://circinterventions.ahajournals.org/content/early/2010/11/09/CIRCINTERVENTIONS.110.944983.abstract?papetoc

Incidence and Management of CoreValve Dislocation During Transcatheter Aortic Valve Implantation

Sarah Geisbüsch, MD, Sabine Bleiziffer, MD, Domenico Mazzitelli, MD, Hendrik Ruge, MD, Robert Bauernschmitt, MD, PhD and Rüdiger Lange, MD, PhD

From the Clinic for Cardiovascular Surgery, German Heart Center Munich, Munich, Germany.

Background—Transcatheter aortic valve implantation is a highly specialized technique offering a new therapeutic option to patients at high risk for conventional surgery. Complications associated with this catheter procedure differ from complications after surgical aortic valve replacement. This is to report incidence, management, and impact on morbidity and mortality of CoreValve dislocation during catheter valve implantation.

Methods and Results—Between June 2007 and September 2009, the self-expandable CoreValve prosthesis (Medtronic Inc, Minneapolis, Minn) was implanted in 212 patients through a transarterial (femoral or subclavian) access. Patients with severe aortic stenosis who were at high risk for conventional surgery were included. We observed dislocation of the prosthesis during CoreValve implantation in 21 patients. In 16 cases, the CoreValve could be implanted in the correct annular position after retrieving it and reloading the catheter. In 4 patients, the completely deployed prosthesis had to be placed in the ascending or abdominal aorta before implanting a second one. One patient underwent open surgery. Overall 30-day mortality was 11.0%, 21.5% in the dislocation group and 9.9% in patients without dislocation (P=0.024). Coronary ischemia, stroke, and renal failure occurred more frequently in patients with dislocation, whereas pacemaker dependency did not differ significantly between the groups.

Conclusions—CoreValve dislocation during transcatheter aortic valve implantation occurred in 10% of the cases and significantly increases perioperative risk for severe complications or death. It requires individual specific management and can be managed either interventionally or, rarely, results in open surgery.

Tuesday, November 9, 2010

Balloon Aortic Valvuloplasty - Long term follow up.

Aortic valve reinterventions after balloon aortic valvuloplasty for congenital aortic stenosis.
JACC 2010;56:1740-9.

Study period: 1985-2008
n=509
(54 patients were excluded: converted to univentricular heart and/or died <30 up =" 9.3" n="70)." n="225)">....these don't add up!

Survival free of reintervention:
89% at 1 yr
72% at 5 yrs
54% at 10 yrs
53% at 20 yrs

In multivariate analysis,
Lower post-dilatation AS gradient & Lower post-dilatation AR were associated with longer freedom from intervention.

Wednesday, November 3, 2010

Common pulmonary vein atresia & ECMO

PEDIATRICS Vol. 91 No. 2 February 1993, pp. 403-410

Common Pulmonary Vein Atresia: The Role of Extracorporeal Membrane Oxygenation

Golde G. Dudell MD1, Marva L. Evans MD1, Henry F. Krous MD2, Robert L. Spicer MD3, , John J. Lamberti MD4

Common pulmonary vein atresia is a rare form of cyanotic congenital heart disease in which the pulmonary veins join to form a blind confluence that does not communicate with the heart or the majorsystemic veins. Twenty-one cases have been reported since the lesion was first described in 1962; only two patients with this lesion have survived. Over a 4-year period, common pulmonaryvein atresia was diagnosed in five newborns referred to the San Diego Regional Extracorporeal Membrane Oxygenation Program. All five improved dramatically as a result of venoarterial bypass.Congenital heart disease was diagnosed at autopsy in the initial case and by cardiac ultrasound and/or catheterization in the others. Surgical repair was attempted in three neonates; all three required continued extracorporeal membrane oxygenation support postoperatively because of pulmonary hypertension and severe pulmonary parenchymal disease. One infant died of respiratory insufficiency at 3 months of age. The other two survived and were discharged from the hospital. The diagnostic and therapeutic dilemmas posed by this lesion and the life-saving potential for extracorporeal membrane oxygenation in this rapidly fatal cardiac anomaly are the bases of this report.

______________________________________________________________________________________________

The Journal of Thoracic and Cardiovascular Surgery, Vol 83, 443-448

Common pulmonary vein atresia: Importance of immediate recognition and surgical intervention

S Khonsari, PW Saunders, MH Lees and A Starr

Common pulmonary vein atresia is a rare congenital anomaly; all four pulmonary veins drain into a common dilated chamber with no direct connections to the heart or systemic venous system. Since its first description in 1962, 16 cases have been reported. Only four patients were surgically managed and none survived. This communication presents the seventeenth reported case of common pulmonary vein atresia and the only patient whose anomaly was suspected early enough to demand immediate surgical management, with gratifying long-term success. The literature on the subject is reviewed and common features of the anomaly are emphasized to facilitate precise diagnosis, so that a futile search for a nonexistent communicating vein is avoided at the time of operation. This approach has led to the first successful surgical management of this otherwise fatal lesion.

______________________________________________________________________________________________

Clinical Features of Neonates with Common Pulmonary Vein Atresia

KAJINO MAYUMI at al.

Abstract;We reviewed four neonates with common pulmonary vein atresia (CPVA) encountered at our institution since 1995. In all patients, chest radiography at birth showed severe pulmonary congestion, air leak and pleural effusion despite normal cardiac silhouette. Arterial blood gas analysis on admission demonstrated marked acidosis with hypoxemia and hypercapnea unresponsive to 100% oxygen and mechanical ventilation. In three patients, CPVA was diagonosed by echocardiography visualizing a small common pulmonary venous chamber behind the left atrium without major drainage veins. In the remaining one patient, a diagnosis of CPVA was established by autopsy. Two patients underwent corrective surgical repair for CPVA. However, these infants could not survive due to intractable hypoxemia. One patient could not proceed to the surgical repair after the diagnosis because of extremely very low birth weight, hypoplastic lungs and trisomy 13 and the infant died of hypoxemia. All four patients died. Autopsy on three patients demonstrated the typical anatomy of CPVA. In all patients, vertical veins were proven and found to be atretic. Two of the patients had dilated pulmonary lymphatic channels on the overall lung surfaces, which microscopic examination confirmed as pulmonary lymphangiectasis. In conclusion, CPVA is fatal despite early diagnosis and surgical correction. The cause of death was intractable hypoxemia due to persistent pulmonary venous obstruction and pulmonary lymphangiectasis.
_________________________________________________________________________________________________

Congenit Heart Dis. 2008 Nov-Dec;3(6):431-4.

Atresia of the common pulmonary vein--a rare congenital anomaly.

Vaideeswar P, Tullu MS, Sathe PA, Nanavati R.

Department of Pathology, Cardiovascular & Thoracic Division, Seth G.S. Medical College, KEM Hospital, Parel, Mumbai, India. shreeprajai@yahoo.co.in

Abstract

OBJECTIVES: Early atresia of the common pulmonary vein (ACPV) leads to total anomalous pulmonary venous drainage, while late atresia or incomplete absorption leads to common pulmonary vein atresia and cor triatriatum sinister (both of which are rare). We report seven cases of atresia of the common pulmonary vein at autopsy.

DESIGN: Retrospective case records studied.

SETTING: Tertiary care teaching hospital affiliated to medical college in Mumbai, India.

PATIENTS AND METHODS: The clinical and autopsy records of neonates and infants diagnosed with ACPV over a period of 11 years were reviewed. The demographic data, clinical features, and results of investigations were correlated with the cardiac findings at necropsy.

RESULTS: Seven neonates and infants (five males and two females) had ACPV. Six babies presented at birth and expired within 48 hours. They had a homogeneous group of symptoms of cyanosis since birth with respiratory distress and/or features of congestive cardiac failure. One had perimembranous ventricular septal defect with bicuspid pulmonary valve and atresia of aortic valve. Two had dysmorphic facial features suggestive of Down's syndrome. Isolated ACPV was seen in only two patients. Asplenia syndrome was seen in three patients. Marked dilatation of the pulmonary lymphatics was identified in three patients.

CONCLUSIONS: Early atresia of the common pulmonary vein, an extremely rare abnormality, manifests in early infancy/neonatal period and needs urgent corrective surgery. It is associated with other congenital heart disorders and extracardiac manifestations as well.

____________________________________________________________________________________________________

This article provides an overall distribution frequencies of different types of drainage & incidence of pulmonary venous obstruction and hypertensive changes in pulmonary arteries.


Pediatr Pathol. 1994 Jul-Aug;14(4):665-78.

Total anomalous pulmonary venous drainage associated with fatal outcome in infancy and early childhood: an autopsy study of 52 cases.

James CL, Keeling JW, Smith NM, Byard RW.

Department of Tissue Pathology, Institute of Medical and Veterinary Science, Adelaide, Australia.

Abstract

Clinicopathological details of 52 cases of total anomalous pulmonary venous drainage (TAPVD) taken from pediatric autopsy files from hospitals in Adelaide (Australia) Oxford and Edinburgh (United Kingdom) between 1957 and 1990 are presented. The patients ranged in age from a stillborn girl to a 15-month-old boy, with 42 cases (81%) dying in the first 3 months of life. While many patients had signs of a congenital cardiovascular anomaly prior to death, including tachypnea, tachycardia, central cyanosis, cardiac failure, heart murmurs, and difficulty in feeding, it was noteworthy that eight patients (16%) presented as sudden and unexpected death in the absence of significant antemortem symptoms and signs. Anomalous pulmonary venous drainage was also unsuspected prior to death in a total of 26 cases (53%) of those where relevant history was available (49 cases). Twelve infants (23%) underwent surgical correction, none of whom survived more than several weeks. TAPVD was isolated in 30 cases (58%) and was associated with other cardiac or congenital anomalies in 22 patients (42%). Just under half of nonisolated cases comprised the asplenia-heterotaxy syndrome. The points of drainage of the anomalous pulmonary veins were to the infradiaphragmatic veins (n = 21, 40%), left innominate vein (n = 13, 25%), coronary sinus (n = 7, 13%), right superior vena cava (n = 4, 8%), inferior vena cava above the diaphragm (n = 2, 4%), right innominate vein (n = 2, 4%), mixed left innominate vein and coronary sinus (n = 1, 2%), azygos vein (n = 1, 2%), and mixed right superior vena cava and left hemiazygos vein (n = 1, 2%). Twenty-three of 47 cases (49%) that were specifically examined revealed obstruction of the pulmonary veins or pulmonary hypertensive vascular changes on histology. These results emphasize that TAPVD needs to be excluded at autopsy as a causal factor in cases of sudden infant death even in the absence of antemortem symptoms and signs. Clues at autopsy include abnormal mobility of the heart, visceral situs inversus, and polyasplenia. The diversity of pulmonary-systemic venous anastomoses necessitates careful in situ dissection above and below the diaphragm and consideration of postmortem angiography.

______________________________________________________________________________________________________________

Pediatr Cardiol. 2001 May-Jun;22(3):255-7.

Successful surgical repair of common pulmonary vein atresia in a newborn.

Suzuki T, Sato M, Murai T, Fukuda T.

Division of Cardiovascular Surgery, Tokyo Metropolitan Children's Hospital, 1-3-1 Umezono, Kiyose-shi, Tokyo 204-8567, Japan.

Abstract

A 7-hour-old boy underwent an emergency operation with an anticipated diagnosis of total anomalous pulmonary venous connection. The precise diagnosis of common pulmonary vein atresia (CPVA) was made during the operation. A side-to-side anastomosis between the common pulmonary venous chamber and the left atrium was performed. All procedures were successfully carried out on the beating heart under the cardiopulmonary bypass. A tentative diagnosis of CPVA should always be borne in minds in neonates with clinical conditions such as deep cyanosis unresponsive to the oxygen therapy, stubborn acidosis, severe pulmonary venous congestion, and rapid deterioration. The corrective repair of CPVA with the heart beating appears to be the procedure of choice in the setting of seriously damaged myocardium of the immature heart. To the best of our knowledge, this is the youngest survivor of the corrective surgery for CPVA and operation at time of diagnosis is the important principle.

____________________________________________________________________________________________________________________________

Annals of Pediatric Cardiology 2009;2:153-5.
Supracardiac anomalous pulmonary venous connection with unilateral pulmonary venous atresia: Diagnosis and management


Department of Pediatric Cardiology, Narayan Hrudayalaya Institute of Cardiac Sciences, Bangalore, India

Introduction Top


Anomalous pulmonary venous connection and drainage are known congenital cardiac anomalies that need early surgical correction. The presence of pulmonary venous stenosis or atresia in this setting may change management options. Thus, their coexistent presence should be specifically looked for during echocardiography.

This case emphasizes the importance of thorough evaluation of individual pulmonary veins before cardiac surgery. Multislice cardiac computed tomography, when indicated, may play a vital role in such an evaluation.


Case Report Top


A 6-day-old, 2.8 kg full-term neonate with a history of fast breathing and feeding difficulty was referred to our hospital for surgical correction of supracardiac total anomalous pulmonary venous connection.

On examination, the baby had severe respiratory distress and central cyanosis with saturation of 72% by a pulse oxymeter. Cardiovascular examination demonstrated a normal first heart sound, wide and fixed split second heart sound and a 2/6 ejection systolic murmur at the pulmonary area. Mechanical ventilation was started along with inotropes. Chest X-ray film showed haziness along with reticulogranular pattern involving the entire right lung. The left lung field was normal [Figure 1]. In retrospect, this pattern was suggestive of differential pulmonary venous congestion.

Transthoracic echocardiography showed left-sided anomalous supracardiac pulmonary venous connection. Left-sided pulmonary veins formed a common chamber behind the left atrium. From there, a right vertical vein ascended and joined the right innominate vein - superior vena cava junction, with a gradient of 11 mmHg a this junction. In addition, a large ostium secundum type of atrial septal defect (shunting right to left) and a small patent ductus arteriosus (shunting bidirectional) were observed. Right- sided pulmonary veins were not clearly seen.

Because the right veins were not clearly defined on transthoracic echocardiography, 64 multislice cardiac computed tomography was performed, which revealed atretic right-sided pulmonary veins with anomalous left-sided pulmonary venous connections and drainage, as described above [Figure 2]. Severe interstitial edema of the right lung was observed.

The case was discussed at our combined Pediatric Cardiology-Cardiac Surgical meeting. Surgical rerouting of unilateral pulmonary veins without addressing right lung issues may lead to persistence of severe pulmonary arterial hypertension (PAH). One option was to transplant the right lung and to reroute the pulmonary veins on the other side. Non-availability of an expert neonatal lung transplantation facility and "donor neonatal lung" along with very high procedural morbidity and mortality precluded such a repair in the neonatal period. Thus, this baby was deemed to be a poor candidate for cardiac surgery.


Discussion Top


Although rare, total anomalous pulmonary venous connection is one of the routine congenital cardiac anomalies seen at tertiary care pediatric cardiac facilities. In most cases, all four pulmonary veins drain into a common chamber that has a variable drainage site. Pulmonary venous atresia is extremely rare with anomalous pulmonary venous connections but can affect management decisions. Etiology of pulmonary venous atresia is believed to be congenital and is related to a somewhat more common focal pulmonary venous stenosis. [1]Improper incorporation of the common pulmonary vein into the left atrium is the embryological basis.

In a study by Makoto et al., nine of 48 patients of anomalous pulmonary venous connection had dysmorphic pulmonary veins. These included excessive tributaries, vertical vein atresia, hypoplastic confluence and focal pulmonary vein stenosis. [1] None had pulmonary venous atresia involving the entire lung.

Older children with isolated unilateral pulmonary venous atresia present with hemoptysis, recurrent pulmonary infections and small lungs with reticulogranular pattern on a chest X-ray film. [2-5] Venous drainage of the involved lung occurs into the azygos vein via the bronchial venous system. [3] Treatment of this condition is lobectomy or pneumonectomy. [2],[3],[4],[5]Isolated pulmonary venous atresia is rare and its association with other congenital heart diseases is even rarer. [2]

Evaluation of individual pulmonary veins is mandatory in a case with anomalous pulmonary venous connections. Takayuki et al. showed that the prospective detection rates of pulmonary venous abnormalities with echocardiography were 38%. [6] Doubtful pulmonary venous anatomy on echocardiography can be further evaluated by cardiac computed tomography scan, which is an excellent diagnostic tool to define the pulmonary venous tree.[7],[8]

In a similar single reported case of infradiaphragmatic pulmonary venous connection and unilateral pulmonary venous atresia, the authors did not operate on their patient and mentioned unfavorable prognosis of such an entity. [9]

In summary, early presentation, discrepancy between clinical condition and degree of pulmonary venous obstruction along with differential pulmonary venous congestion on chest X-ray film are important bedside clues to look for pulmonary venous hypoplasia/atresia, such as diagnosed in our case above. Unilateral small pulmonary artery (if present) is another clue for pulmonary venous hypoplasia/atresia, which is in contrast to dilated pulmonary arteries of classic total anomalous pulmonary venous connection. [10]

Pre-surgical evaluation of individual pulmonary veins in congenital cardiac cases, especially those with anomalous pulmonary venous connections, prevents errors in management. Multislice cardiac computed tomography scan plays a vital role in accurate diagnosis of this rare entity.

References Top

1.Ando M, Takahashi Y, Kikuchi T. Total anomalous pulmonary venous connection with dysmorphic pulmonary vein: A risk for postoperative pulmonary venous obstruction. Interact Cardiovasc Thorac Surg 2004;3:557-61. Back to cited text no. 1
2.Pourmoghadam KK, Moore JW, Khan M, Geary EM, Madan N, Wolfson BJ, et al. Congenital unilateral pulmonary venous atresia: Definitive diagnosis and treatment. Pediatr Cardiol 2003;1:73-9. Back to cited text no. 2
3.Cullen S, Deasy PF, Tempany E, Duff DF. Isolated pulmonary vein atresia. Br Heart J 1990;63:350-4. Back to cited text no. 3
4.Kingston HM, Patel RG, Watson GH. Unilateral absence or extreme hypoplasia of pulmonary veins. Br Heart J 1983;49:148-53. Back to cited text no. 4
5.Swischuk LE, L'Heureux P. Unilateral pulmonary vein atresia. AJR Am J Roentgenol 1980;135:667-2. Back to cited text no. 5
6.Masui T, Seelos KC, Kersting-Sommerhoff BA, Higgins CB. Abnormalities of the pulmonary veins: Evaluation with mr imaging and comparison with cardiac angiography and echocardiography. Radiology 1991;181:645-9. Back to cited text no. 6
7.Heyneman LE, Nolan RL, Harrison JK, McAdams HP. Congenital unilateral pulmonary vein atresia: Radiologic findings in three adult patients. AJR Am J Roentgenol 2001;177:681-5. Back to cited text no. 7
8.Daltro P, Fricke BL, Kuroki I, Domingues R, Donnelly LF. CT of congenital lung lesions in pediatric patients. AJR Am J Roentgenol 2004;5:1497-506. Back to cited text no. 8
9.Samαnek M, Tόma S, Benesovα D, Povύsilovα V, Prazskύ F, Cαpova E. Atresia of right pulmonary veins and anomalous left pulmonary venous drainage into portal circulation. Thorax 1974;29:446-50. Back to cited text no. 9
10.Beerman LB, Oh KS, Park SC, Freed MD, Sondheimer HM, Fricker FJ, et al. Unilateral pulmonary vein atresia: Clinical and radiographic spectrum. Pediatr Cardiol 1983;2:105- 12. Back to cited text no. 10


Bicuspid Aortic Valve - Etiology and Associated Lesions

The following letter to the editor highlights other articles that deal with different etiologies for different morphologies of bicuspid aortic valve. Worth reading them all!

J Am Coll Cardiol, 2010; 56:1680, doi:10.1016/j.jacc.2010.03.073
Bicuspid Aortic Valve Morphology
Alexander R. Opotowsky, MD, MPH* andMichael J. Landzberg, MD

* Children's Hospital Boston, Boston Adult Congenital Heart Service, Department of Cardiology, 300 Longwood Avenue, Boston, Massachusetts 02115 (Email:alexander.opotowsky@childrens.harvard.edu).


We read with interest and appreciation 3 recent papers in the Journal on the bicuspid aortic valve (BAV).

Fernandez et al. (1) describe distinct developmental patterns for mice and hamsters with right-noncoronary and right-left coronary cusp fusion, respectively. Incredibly, William Osler anticipated, within the limitations of his era, these findings and their significance more than a century ago:

If it turns out to be correct ... that the affected valves are usually those behind ... the coronary arteries ... this would point to some error associated especially with the development of these cusps. It would appear from the observations of Tonge, that two of the segments are formed before the division of the primitive truncus arteriosus is complete, while the third arises laterafter the pulmonary artery and the aorta have divided. It is not at all improbable that we may have here a clew to an explanation of this anomaly, but this is conjectural until we have fullerdetails of the process of the development of the sigmoid valves in mammals (2).

As it becomes increasingly apparent that right-noncoronary and right-left coronary cusp fusion are distinct diseases, research reports on the BAV should make this distinction as Osler suggested: "This point [right-left coronary cusp fusion is the most common BAV morphology], previously overlooked, may prove of interest in the etiology, and should be carefully noted in future observations" (2).

Biner et al. (3) report evidence of a bicuspid aortopathy in first-degree relatives of BAV patients, but did not address the relationship of BAV morphology to aortic properties. We would be interested to know whether BAV morphology in the proband modifies the extent of aortic dilation and stiffness in first-degree relatives.

Tzemos et al. (4) provide data suggesting that the BAV is associated with endothelial dysfunction, at least in the presence of aortic dilation. The authors note that three-fourths of the patients in each BAV group had anteroposterior aortic leaflet orientation (presumably right-left coronary cusp fusion), but no data arepresented on the relationship between BAV morphology and the parameters studied. Does BAV morphology influence the relationship among aortic dilation, aortic stiffness, serum matrix metalloproteinaselevels, and endothelial function?

With deepening understanding of the developmental and physiologic aspects of the BAV and its associated diffuse vasculopathy, we believe that it is vital that data be reported to allow detailed inquiry into potential variation between morphologically and likely clinically and developmentally distinct categories of disease.

References:

1. Fernandez B, Duran AC, Fernandez-Gallego T, et al. Biscupid aortic valves with different spatial orientations of the leaflets are distinct etiological entities J Am Coll Cardiol 2009;54:2312-2318.[Abstract/Free Full Text]

2. Osler W. The Bicuspid Condition of the Aortic Valves. . Transactions of the Association of American Physicians. Philadelphia: Wm. J. Dornan; 1886. pp. 185-192.

3. Biner S, Rafique AM, et al. Aortopathy is prevalent in relatives of bicuspid aortic valve patients J Am Coll Cardiol 2009;53:2288-2295.[Abstract/Free Full Text]

4. Tzemos N, Lyseggen E, Silversides C, et al. Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta J Am Coll Cardiol 2010;55:660-668.[Abstract/Free Full Text]

Also see other posting on this subject